antibody-design
(3)
Nabla Bio
Nabla Bio is a Cambridge, Massachusetts biotech building AI plus wet-lab technology to design antibodies and protein therapeutics from scratch. Its Joint Atomic Modeling (JAM) platform generates de novo binders against historically undruggable membrane proteins like GPCRs, and the company has signed collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth over a billion dollars in potential payments.
BigHat Biosciences
BigHat Biosciences is a San Mateo biotech using machine learning and a high-speed wet lab to design safer, more effective therapeutic antibodies. Its Milliner platform iterates between in-silico design and physical molecules in days, optimizing biologics across binding, stability, immunogenicity and developability for partners like Merck and Johnson & Johnson.
Profluent
Profluent is an AI-first protein design company building frontier models that author novel proteins - including the first AI-designed CRISPR gene editor, OpenCRISPR-1. Based in Berkeley's biotech corridor, the company applies the same scaling-law playbook that worked for language models to the language of biology, then validates the outputs in a wet lab.